Clinical governance experts

Clinical governance sets the standards, quality systems, consent and long-term follow-up that gene therapy and stem cell programmes run under across jurisdictions.

2 experts, updated 20 Oct 2026

What our clinical governance experts do

The first task is fixing the standard a programme will run to: the regulatory requirements that apply at each site, and the single internal standard that applies everywhere regardless of jurisdiction. From that come the written protocols, the consent documents patients sign, the quality records covering what was manufactured, dosed and observed, and the long-term follow-up schedule that keeps patients under review for years after a gene therapy or stem cell product is administered. Every site is qualified against the same documents before it opens, and deviations are logged, reviewed and closed out rather than noted.

How they work

Clinical governance experts put most of their judgement into consent and follow-up, because a gene therapy cannot be withdrawn once it has been dosed and the duty of care outlives the trial. Triple Helix Science writes its therapeutic protocols in house as proprietary work rather than licensing them in, so the governance documents and the science they govern are drafted by the same organisation and move together when a protocol changes. The harder cases are combination work, where stem cell biology and targeted gene therapy sit in one protocol and two evidence standards have to be reconciled without lowering either.

When to bring them in

Bring clinical governance experts in before a programme moves beyond its first site, not after. The usual trigger is scale: a protocol proven in one centre that a government or sovereign health system now wants delivered across a national population, with several jurisdictions, several regulators and one safety record between them. The other trigger is duration, when follow-up obligations run years past the last dose and somebody has to own them. Triple Helix Science works with institutions on this, including governments, research universities and pharmaceutical organisations, rather than with individual patients.

Media reaction

Preventative care and emerging health systems

"Healthcare is shifting from treating illness to preventing it, and that will transform patient outcomes and health systems alike. The biggest opportunity lies with governments in emerging economies building from scratch. Free of legacy infrastructure, they can deliver next-generation care at scale or become international hubs for treatment."
Dr Christopher JensenDr Christopher Jensen, Chief Operating Officer, Triple Helix Science20 Oct 2026
1 of 2

Questions about clinical governance experts

The questions we get asked most about clinical governance, answered plainly.

What is clinical governance in gene therapy and stem cell research?
Clinical governance is the system of standards, quality controls, consent processes and long-term participant follow-up that a clinical programme operates under. In gene therapy, regenerative medicine and stem cell science it carries further than in conventional drug work, because a genetic or cellular intervention is not withdrawn when dosing stops. Clinical governance is what makes a therapeutic protocol auditable by a regulator, an ethics committee or a sovereign health system.
What does a clinical governance expert actually do on a research programme?
A clinical governance expert writes the protocol a programme runs to, sets the consent language participants sign, defines how tissue, cells and participant data are handled and traced, qualifies each site before it opens, and fixes the follow-up schedule after dosing. Where a programme runs across more than one country, the same expert reconciles the differing national requirements into a single operating standard rather than letting each site interpret the protocol locally.
How is clinical governance judged on a programme?
Clinical governance is judged on whether the record can be produced on demand: every site running the current protocol version, consent traceable to each named participant, adverse events reported inside the stated window, and follow-up contact held over years rather than decaying after the dosing phase. Triple Helix Science reports completing a Phase 1 human trial showing reversal of dementia progression, and a result of that weight is only usable institutionally if the governance record behind it stands up to audit.
Is clinical governance the same as regulatory affairs?
No. Regulatory affairs manages the relationship with the regulator, which means submissions, dossiers, approvals and correspondence. Clinical governance determines what happens inside the clinic and the laboratory every day: who may consent a participant, how a cell product is released, what gets escalated and how fast. A programme can hold every approval it needs and still fail on governance, which is where patient harm and unusable data come from.
When does a research programme need clinical governance support?
A programme needs clinical governance in place before the first human dose, and again before it adds sites, crosses a border, or moves from trial to delivery inside a national health system. Purely preclinical work with no human participants does not need the full framework yet, though donor tissue provenance and consent still apply from the moment human material is used. Triple Helix Science works at the institutional level with governments, sovereign health systems, research universities and pharmaceutical organisations rather than with individual patients.

Contact an expert

Get in touch with an expert on clinical governance for comment, an interview or a question.

Straight to the Triple Helix Science press team.